A systematic review synthesizes clinical evidence on a B-cell–targeting biologic for myasthenia gravis, focusing on outcomes, steroid reduction, and safety.
Key Takeaways
- Telitacicept treatment in myasthenia gravis consistently reduced disease severity scores
- Several studies reported that telitacicept enabled reductions in glucocorticoid doses
- Short-term adverse events were generally mild and transient